Boulevard: Homing in on B cell biology in autoimmunity

B cell biology is the theme underlying Deerfield-incubated Boulevard Bio, which launched this week with a trio of B cell-directed assets in development for IgA nephropathy and other autoimmune diseases. With autoimmune CAR T trailblazer Georg Schett and former Sanofi CSO Frank Nestle as scientific co-founders, the company believes it’s well-positioned to deliver best-in-class therapies for patients.

Boulevard Bio Inc. made its official debut on Wednesday with $65 million in aggregate funding from Deerfield Management, a long-acting APRIL x BAFF bispecific for IgA nephropathy in Phase I, and a pair of preclinical therapies for autoimmune diseases...